CLAIMS

1. A method of screening for agents which can regulate the activity of a human phospholipase-like enzyme, comprising the steps of:

contacting a test compound with a polypeptide comprising an amino acid sequence which is at least about 78% identical to the amino acid sequence shown in SEQ ID NO:2; and

detecting binding of the test compound to the polypeptide, wherein a test compound which binds to the polypeptide is identified as a potential therapeutic agent for regulating the activity of the human phospholipase-like enzyme.

2. The method of claim 1 wherein the step of contacting is in a cell.

3. The method of claim 2 wherein the cell is *in vitro*.

4. The method of claim 1 wherein the step of contacting is in a cell-free system.

5. The method of claim 1 wherein the polypeptide comprises a detectable label.

6. The method of claim 1 wherein the test compound comprises a detectable label.

7. The method of claim 1 wherein the test compound displaces a labeled ligand which is bound to the polypeptide.

8. The method of claim 1 wherein the polypeptide is bound to a solid support.

9. The method of claim 1 wherein the test compound is bound to a solid support.

10. A method of screening for agents which regulate an activity of a human phospholipase-like enzyme, comprising the steps of:

contacting a test compound with a polypeptide comprising an amino acid sequence which is at least about 78% identical to the amino acid sequence shown in SEQ ID NO:2; and

detecting a phospholipase activity of the polypeptide, wherein a test compound which increases the phospholipase activity is identified as a potential therapeutic agent for increasing the activity of the human phospholipase-like enzyme, and wherein a

test compound which decreases the phospholipase activity of the polypeptide is identified as a potential therapeutic agent for decreasing the activity of the human phospholipase-like enzyme.

11. The method of claim 10 wherein the step of contacting is in a cell.

12. The method of claim 11 wherein the cell is *in vitro*.

13. The method of claim 10 wherein the step of contacting is in a cell-free system.

14. A method of screening for agents which regulate an activity of a human phospholipase-like enzyme, comprising the steps of:

contacting a test compound with a product encoded by a polynucleotide which comprises a nucleotide sequence which is at least about 50% identical to the complement of the nucleotide sequence shown in SEQ ID NO:1; and

detecting binding of the test compound to the product, wherein a test compound which binds to the product is identified as a potential therapeutic agent for regulating the activity of the human phospholipase-like enzyme.

15. The method of claim 14 wherein the product is a polypeptide.

16. The method of claim 14 wherein the product is RNA.

17. A method of reducing activity of a human phospholipase-like enzyme, comprising the step of:

contacting a cell with a reagent which specifically binds to a product encoded by a polynucleotide comprising a nucleotide sequence which is at least about 50% identical to the nucleotide sequence shown in SEQ ID NO:1, whereby the activity of the human phospholipase-like enzyme is reduced.

18. The method of claim 17 wherein the product is a polypeptide.

19. The method of claim 18 wherein the reagent is an antibody.

20. The method of claim 17 wherein the product is RNA.

21. The method of claim 20 wherein the reagent is an antisense oligonucleotide.

22. The method of claim 20 wherein the reagent is a ribozyme.

23. The method of claim 17 wherein the cell is *in vitro*.

24. The method of claim 17 wherein the cell is *in vivo*.

25. A pharmaceutical composition, comprising:

a reagent which specifically binds to a product encoded by a polynucleotide comprising a nucleotide sequence which is at least about 50% identical to the nucleotide sequence shown in SEQ ID NO:1; and

a pharmaceutically acceptable carrier.

26. The pharmaceutical composition of claim 25, wherein the reagent is an antibody.

27. The pharmaceutical composition of claim 25, wherein the reagent is an antisense oligonucleotide.

28. The pharmaceutical composition of claim 25, wherein the reagent is a ribozyme.

29. A pharmaceutical composition, comprising:

an expression construct encoding a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2; and

a pharmaceutically acceptable carrier.